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BACKGROUND: Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating
endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic phenotype of renal cell carcinoma
(RCC), we sought to assess the potential of CECs as a marker of RCC in patients with von Hippel-Lindau (VHL) disease and those
with sporadic RCC.
METHODS: We performed multicolour flow cytometry to enumerate CECs in patients with RCC, patients with VHL disease with and
without RCC, and normal subjects. Two subsets of CECs were evaluated: mature CECs (mCECs) and circulating endothelial
progenitors (CEPs).
RESULTS: In patients with VHL disease and RCC and those with sporadic RCC (N¼10), CEPs and the CEP:mCEC ratio were higher
than in normal subjects (N¼17) (median CEPs: 0.97 vs 0.19 cellsml
 1, respectively, Po0.01; median CEP:mCEC: 0.92 vs 0.58,
respectively, P¼0.04). However, in patients with VHL without RCC, CECs were not increased. In paired pre- and post-nephrectomy
RCC patient samples (N¼20), CEPs decreased after surgery (median difference 0.02 cellsml
 1,  0.06 to 1.2; P¼0.05).
CONCLUSION: Circulating endothelial progenitors were elevated in RCC, but not in patients with VHL without RCC. Circulating
endothelial progenitor enumeration merits further investigation as a monitoring strategy for patients with VHL.
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Renal cell carcinomas (RCCs) are the most frequent malignant
tumours to occur in patients with von Hippel-Lindau (VHL)
disease, and VHL disease is the primary cause of inherited renal
cancer. von Hippel-Lindau disease affected individuals are at risk
for the development of up to 600 clear cell renal carcinomas per
kidney (Kaelin, 2008). von Hippel-Lindau disease arises from
heterozygous germline mutations in the VHL tumour suppressor
gene, which resides on chromosome 3p25, and it is characterised
by clear cell RCC, hemangiomas, pheochromocytomas, and other
tumour types (Linehan et al, 2003). The development of tumours
in VHL disease results from loss or inactivation of the remaining
wild-type allele, leading to an absence of functional VHL protein.
Somatic VHL mutations are also common in sporadic clear
cell RCC and hemangioblastomas (Linehan et al, 2003). Restora-
tion of VHL protein function is sufficient to suppress tumour
formation in vivo in VHL-defective renal carcinoma cells (Linehan
et al, 2003).
The VHL gene encodes an E3 ligase involved in the oxygen-
dependent ubiquitination and proteasomal degradation of the
hypoxia-inducible factors HIF-1a and HIF-2a, subunits of
transcriptional factors involved in the expression of vascular
endothelial growth factor (VEGF) and other hypoxia-driven genes.
The loss of VHL protein results in the accumulation of HIF (even
in normoxic conditions) and the overproduction of VEGF and
other mediators of angiogenesis (Linehan et al, 2003). As a result,
RCCs are highly vascular tumours and are responsive to therapy
with agents that interfere with VEGF signalling.
RCCs often remain asymptomatic for long intervals before
diagnosis. In patients with VHL, who also develop RCC, the
frequent absence of clinical symptoms underscores the importance
of early detection, as diagnosis during presymptomatic screening
has the potential to enhance overall outcomes. Although serial
imaging of the kidneys is useful in this regard, more effective
strategies for monitoring patients with VHL disease are needed.
Also, new biomarkers for disease recurrence after nephrectomy in
patients with sporadic RCC could indicate the early need for
intervention.
Circulating endothelial cells (CECs) are a candidate biomarker
for monitoring angiogenesis in patients with VHL disease and in
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sthose with RCC. Circulating endothelial cells are known to express
VEGF receptors and to be mobilised by VEGF in patients and
murine models, and they have been found at increased levels in
cancer patients (Asahara et al, 1997, 1999; Kalka et al, 2000;
Peichev et al, 2000; Mancuso et al, 2001; Schuch et al, 2003;
Ceradini et al, 2004) including RCC (Gruenwald et al, 2010). Two
main types of CECs have been described: mature CECs (mCECs),
which are thought to be shed from preexisting blood vessels, and
bone marrow-derived circulating endothelial progenitors (CEPs).
Circulating endothelial progenitor mobilisation has been shown to
depend on HIF-regulated factors such as VEGF and SDF-1a.
Furthermore, mCECs and CEPs may respond differently to
angiogenic stimuli and provide distinct information regarding
angiogenic drive and response to treatment (Bertolini et al, 2003;
Beaudry et al, 2005; Shaked et al, 2005; Batchelor et al, 2007). Thus,
because of the highly angiogenic phenotype of RCC and its
dependence on HIF and HIF-regulated factors, we sought to assess
the potential of using mCECs and CEPs as potential biomarkers of
RCC in the VHL patient population and also in patients with
sporadic RCC. We hypothesised that CEPs, and the ratio of CEPs
to mCECs, would be altered in RCC patients but not in VHL
patients without RCC.
MATERIALS AND METHODS
Patient population
Patients and healthy control subjects, whose disease status was
assessed radiologically, were enroled in IRB-approved protocols at
Beth Israel Deaconess Medical Center (Boston, MA, USA) and The
University of Texas MD Anderson Cancer Center (Houston, TX,
USA). Patients with sporadic RCC and those with VHL–RCC were
covered by a Dana-Farber–Harvard Cancer Center tissue-collec-
tion protocol and an MD Anderson laboratory-collection protocol
that enabled blood sampling before and after nephrectomy.
For the purposes of this study, we divided those trial
participants into various cohorts as follows: (a) Patients with
VHL disease (N¼13), including those with no radiologic evidence
of RCC but with benign tumours in the brain, eye, kidney, spinal
cord, or pancreas, or a history of resected RCC (N¼7); and
additional patients with VHL and active RCC (VHL–RCC; N¼6);
(b) Patients with sporadic metastatic RCC (N¼4;); (c) Individual
patients with non-metastatic sporadic RCC (N¼20) who under-
went nephrectomy; paired blood samples were obtained within
4 weeks before nephrectomy and 6 weeks to 6 months
after nephrectomy; (d) Healthy control subjects (N¼17); and
(e) Additional healthy control subjects (N¼18) and patients with
sporadic metastatic RCC (N¼9) as an independent validation
cohort for CEPs.
Blood collection
Peripheral blood of patients was collected in Vacutainer CPT tubes
with citrate (BD Biosciences, Franklin Lakes, NJ, USA) and spun to
separate the PBMC layer as previously described (Kalka et al, 2000;
Peichev et al, 2000; Norden-Zfoni et al, 2007). The PBMCs were
frozen and stored in liquid nitrogen until the day of analysis.
Flow cytometry
Batch analysis of PBMCs was performed to minimise interassay
variability. Circulating endothelial cells were enumerated by using
four-colour flow cytometry as described previously (Beaudry et al,
2005; Norden-Zfoni et al, 2007; Mancuso et al, 2009). Briefly, cells
were washed with PBS with 1% albumin and incubated with a
panel of antibodies to establish CEC phenotype, including anti-
CD45, -CD31, -CD146, and -CD133 (BD Biosciences, San Jose, CA,
USA). The mCECs were defined as staining negatively for the
haematopoietic marker CD45, positively for the endothelial
markers CD31 and CD146, and negatively for the progenitor
marker CD133. Circulating endothelial progenitors had the same
phenotype except they were positive for CD133. Human umbilical
vein endothelial cells (Cambrex, East Rutherford, NJ, USA) were
used as positive controls for endothelial marker staining, and
WERI cells (American Type Culture Collection, Manassas, VA,
USA) were used as positive controls for CD133. CD146 was not
available for the validation set, and only CEPs were determined.
The percentages of stained cells were determined by comparison
with the appropriate fluorescent isotype controls.
To establish absolute CEC counts, the volume of blood analyzed
was determined by using the lymphocyte or monocyte counts
obtained from the patients’ differential.
Statistical analysis
Exact Wilcoxon rank-sum testing was used to compare CEP and
mCEC counts and mCEP:CEC ratios between groups. For the 20
patients who underwent nephrectomy, Wilcoxon signed-rank test
was used to look at changes in those values in terms of absolute
differences between the samples collected before and after
nephrectomy.
RESULTS
CEP and mCEC counts are higher in RCC patients than in
healthy control subjects
PBMC fractions from patients with RCC and healthy control
subjects were analyzed for CEP and mCEC counts by using
multiparametric flow cytometry (Norden-Zfoni et al, 2007;
Mancuso et al, 2009). As shown in Figure 1, the absolute numbers
of CEPs and mCECs for individual patients were higher in those
with RCC (N¼10, four with sporadic RCC and six with VHL–
RCC) than they were in the healthy control subjects (N¼17), with
wide variability within the RCC cohort. In RCC patients vs healthy
control subjects, the median numbers (range) of CEPs and mCECs
were 0.97 cellsml
 1 (0.39–5.88) vs 0.19 cellsml
 1 (0.08–0.47;
Po0.01) and 0.93 cellsml
 1 (0.19–11.75) vs 0.33 cellsml
 1 (0.12–
0.99; P¼0.05), respectively (Figure 2).
Similar differences were seen in the independent CEP validation
cohort: the median number (range) of CEPs in RCC patients
(N¼9) was 1.4 cellsml
 1 (0.09–11.99) vs 0.40 cellsml
 1 (0.17–1.89)
in healthy control subjects (N¼18; Po0.05).
CEP:mCEC ratios are higher in RCC patients than in
healthy control subjects
Previous studies have shown that various anti-cancer therapies can
have different effects on CEPs and mCECs. For example, some
VEGF inhibitors have been shown to increase mCECs, whereas
decreasing CEPs in preclinical models (Beaudry et al, 2005). To
investigate this further, we evaluated the CEP:mCEC ratios in RCC
patients and healthy control subjects. We found that RCC patients
(N¼10) had a median CEP:mCEC ratio of 0.92 (range 0.39–7.52),
which was greater than that in the control subjects (N¼17; median
0.58, range 0.10–1.70; Po0.05; Figure 3).
CEP counts and CEP:mCEC ratios are higher in VHL–RCC
patients than in VHL patients without RCC
When compared with the patients with sporadic RCC plus those
with VHL–RCC (total N¼10), the patients with VHL but no RCC
(N¼13) had fewer CEPs, with a median (range) of 0.15 cellsml
 1
(0.07–0.55) vs 0.97 cellsml
 1 (0.39–5.88) (Po0.01) and also
fewer mCECs, with 0.26 cellsml
 1 (0.11–2.11) vs 0.93 cellsml
 1
(0.19–11.75) (P¼0.02) (Figures 4A and B).
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sWe additionally compared CEP and mCEC counts and CEP:mCEC
ratios from the VHL–RCC patients (N¼6) with those from the
patients with VHL and no RCC (N¼13). Patients with VHL–RCC
had more CEPs and higher CEP:mCEC ratios than patients with VHL
without RCC (CEPs, 2.96 cellsml
 1 vs 0.15 cellsml
 1, Po0.01;
CEP:mCEC, 1.36 vs 0.44, P¼0.02) (Figures 5A and C). The VHL–
RCC patients also had more mCECs than the VHL patients without
RCC had, but the difference was not statistically significant (0.89 vs
0.26 cellsml
 1; P¼0.11) (Figure 5B).
CEPs and mCEC counts and CEP:mCEC ratios are
comparable in VHL patients with no RCC and healthy
control subjects
No difference in CEPs and mCEC counts (Figures 4C and D) and
CEP:mCEC ratios were found between the VHL patients with
no RCC (N¼13) and the healthy control subjects (N¼17; all
P values 40.05).
CEP counts decrease after nephrectomy in patients with
non-metastatic sporadic RCC
To further test whether CEP counts correlate with the presence of
RCC, we studied paired PBMC specimens from a separate cohort of
patients with sporadic RCC before and after nephrectomy (N¼20).
These patients had RCC confined to the kidney and no evidence of
metastatic disease. In this patient cohort, the CEP counts
decreased after nephrectomy: the median change (range) between
before and after nephrectomy was 0.02 cellsml
 1 ( 0.06 to 1.2,
P¼0.05). In contrast, the mCEC counts showed large variability,
and the CEP:mCEC ratio did not change significantly between
before and after nephrectomy (Table 1).
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Figure 2 Box plots demonstrate that RCC patients have more CEPs and mCECs than healthy control subjects have. Data (medians and ranges) are from
10 patients with RCC (4 with sporadic non-metastatic RCC and 6 with VHL–RCC) and 17 healthy control subjects. The thick horizontal line within each
box is the median value; the upper and lower boundaries of the boxes are the 75th and 25th percentiles. The bars above and below the boxes are placed at
the observed values closest to the 75th percentile plus 1.5 times the interquartile range (75th percentile minus 25th percentile) and closest to the 25th
percentile minus 1.5 times the interquartile range; observations outside those limits are plotted separately and represented with a small circle. Observations
more extreme than 6 were excluded from these figures.
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Figure 1 Graphs show the absolute numbers of CEP and mCEC cells (per microlitre) in individual RCC patients (N¼10, 4 with sporadic non-metastatic
RCC and 6 with VHL–RCC) and healthy control subjects (N¼17). Number of cells varied widely within the RCC patient cohort.
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sDISCUSSION
von Hippel-Lindau disease predisposes patients to clear cell RCC, a
highly vascular tumour type that frequently involves activation of
the HIF pathway, an established regulator of VEGF and other
angiogenic cytokines. Given that several of these factors are known
to increase the numbers of mCECs and CEPs in the circulation of
human subjects (Kalka et al, 2000; Beaudry et al, 2005; Farace et al,
2007), we compared the CEC counts in healthy control subjects
with those in patients with VHL with and without RCC and in
patients with sporadic RCC. We found in two independent cohorts
that RCC patients have more CEPs (and higher CEP:mCEC ratios)
than healthy control subjects do and that in RCC patients, the CEP
count decreases after surgical removal of the primary tumour
(i.e., nephrectomy). Although it was not the primary focus of this
study, it is also worth noting that patients with VHL plus tumours
other than RCC have fewer CEPs and lower CEP:mCEC ratios
than patients with VHL–RCC have, suggesting that RCC may
promote CEP increase to a greater extent than other tumours in
VHL patients.
These findings are consistent with the biology of VHL disease, in
which HIF levels and VEGF signalling are increased (Ohh et al,
2000; Rini and Small, 2005). von Hippel-Lindau itself in the
absence of RCC did not lead to significant differences in overall
CEC numbers, suggesting that the development of renal cancer,
and not merely the presence of VHL mutation, is associated with
the increase in CEPs. Possibly, this observation reflects the greater
production of VEGF or other factors known to promote the
survival and/or mobilisation of CEPs and other bone marrow-
derived cells by renal cancer tissue, although the specific factor(s)
contributing to the relatively elevated levels of CEPs in this study
are not known.
Thus, it is possible that counting the CEC subsets, particularly
the CEPs, would be a means of surveillance of VHL patients at risk
for developing RCC. Moreover, given that patients with stage IV
RCC have more CECs than are present after nephrectomy for
localised disease, CECs could also be useful as biomarkers for
detecting early disease recurrence in patients who have undergone
such nephrectomy. The results of more detailed studies to relate
disease site and tumour burden with CEC counts may provide
further support for the use of CEC analysis in RCC surveillance.
Patients with RCC also had a higher CEP:mCEC ratio than both
the healthy control subjects and the VHL patients without RCC
had. We propose that the CEP:mCEC ratio may serve as a novel
biomarker reflecting the balance of angiogenic drive of the host as
reflected in the blood. Indeed, in both preclinical models and
phase I/II clinical trials, treatment with antiangiogenic agents has
been shown to inhibit CEP mobilisation (Daenen et al, 2009) and
exert different effects on CEPs and mCECs (Beaudry et al, 2005).
Moreover, antiangiogenic therapy induces dynamic changes in
CEPs and mCECs that may correlate with clinical benefit: earlier
studies conducted by our group and others found CECs useful as a
surrogate marker for antiangiogenic therapy (Beaudry et al, 2005;
Shaked et al, 2005; Norden-Zfoni et al, 2007; Calleri et al, 2009;
Willett et al, 2009), as an aid in selecting optimal dosing (Shaked
et al, 2005), and in assessing benefit to patients (Norden-Zfoni
et al, 2007; Vroling et al, 2009). For example, specific changes in
CEC counts or CEP:mCEC ratio may be useful as a marker for
predicting a patient’s prognosis or response to therapy with VEGF
receptor inhibitors.
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Figure 4 Box plots demonstrate that the cohort of patients with sporadic RCC plus those with VHL–RCC (total N¼10) has more CEPs (A) and
mCECs (B) than the VHL patients with no RCC (N¼13) have. As C and D show, no differences in CEP and mCEC counts were found between the cohort
of patients with VHL without RCC (N¼13) and the cohort of healthy control subjects (N¼17). Plots are read as described in Figure 2.
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Figure 3 Box plot shows that RCC patients also have a higher
CEP:mCEC ratio than healthy control subjects have. Plot is read as
described in Figure 2. Observations more extreme than 2 were excluded
from these figures.
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VEGF receptor inhibitors in RCC patients are under way, but
common problems have been the different criteria used for
defining CECs and the difficulty in accurately counting these rare
cells (Bhatt et al, 2007; Calleri et al, 2009; Mancuso et al, 2009). As
CEC counts vary widely within the population of patients with
RCC, serial measurements in individual patients may prove
especially interesting. Additionally, RCC patients with different
cytokine profiles and CEC responses may require different
management. Studies with larger numbers of RCC patients treated
with angiogenesis inhibitors and other agents will be required to
resolve these questions.
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